medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2016, Número 2

Siguiente >>

Biotecnol Apl 2016; 33 (2)


Estrés oxidativo en la epilepsia resistente a fármacos

Lorigados L, Morales LM, Orozco-Suárez S, Gallardo JM, Díaz-Hung ML, González ME, Estupiñán B, Pavón N, Rocha L

Idioma: Ingles.
Referencias bibliográficas: 114
Paginas: 2101-2107
Archivo PDF: 296.11 Kb.


RESUMEN

La epilepsia resistente a fármacos es una condición que afecta a una proporción sustancial de pacientes tratados con los fármacos antiepilépticos disponibles, los que devienen refractarios a la terapia. Coincidentemente, los fármacos antiepilépticos han sido relacionados con procesos de estrés oxidativo (OS), lo cual puede impactar en la progresión de la enfermedad y ser relevante para el sucesivo desarrollo de fármacos. En esta revisión se analizan los procesos de OS vinculados a la epilepsia resistente a fármacos, que derivan en procesos de exitotoxicidad, neuroinflamación o disfunción mitocondrial, que se han manifestado en otros desórdenes neurológicos y particularmente en la epilepsia. Se muestran evidencias basadas en datos obtenidos mediante el estudio de la epilepsia del lóbulo temporal (ELT) en modelos animales, que derivan en daño a las proteínas, los lípidos y las defensas antioxidantes. Se incluye una vista general emergente sobre la relación del OS y los mediadores solubles involucrados de la inflamación y la escitotoxicidad. Además, se discuten nuevos abordajes terapéuticos, como los propuestos para complementar las terapias existentes o incluso nuevas estrategias para interferir los cambios crónicos inducidos por los ataques recurrentes para un mejor control de la progresión de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Epilepsy Fact Sheet. 2016 Feb [2016 Feb 7]. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/

  2. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991;32(4):429-45.

  3. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999;34(2- 3):109-22.

  4. Henshall DC, Meldrum BS. Cell death and survival mechanisms after single and repeated brief seizures. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper’s Basic Mechanisms of the Epilepsies. 4th ed. Bethesda (MD)2012.

  5. Fujikawa DG, Shinmei SS, Cai B. Kainic acid-induced seizures produce necrotic, not apoptotic, neurons with internucleosomal DNA cleavage: implications for programmed cell death mechanisms. Neuroscience. 2000;98(1):41-53.

  6. Hamed SA, Abdellah MM, El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci. 2004;96(4):465-73.

  7. Solowiej E, Sobaniec W. [The effect of antiepileptic drug therapy on antioxidant enzyme activity and serum lipid peroxidation in young patients with epilepsy]. Neurol Neurochir Pol. 2003;37(5):991-1003.

  8. Karikas GA, Schulpis KH, Bartzeliotou A, Regoutas S, Thanopoulou C, Papaevangelou V, et al. Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities. Scand J Clin Lab Invest. 2009;69(1):31-5.

  9. Patel M. Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic Biol Med. 2004;37(12):1951-62.

  10. Azam F, El-Gnidi BA, Alkskas IA. Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen- 1-yl)semicarbazides. Eur J Med Chem. 2010;45(7):2817-26.

  11. Azam F, Prasad MV, Thangavel N. Targeting oxidative stress component in the therapeutics of epilepsy. Curr Top Med Chem. 2012;12(9):994-1007.

  12. Martinc B, Grabnar I, Vovk T. The role of reactive species in epileptogenesis and influence of antiepileptic drug therapy on oxidative stress. Curr Neuropharmacol. 2012;10(4):328-43.

  13. Sobaniec W, Solowiej E, Kulak W, Bockowski L, Smigielska-Kuzia J, Artemowicz B. Evaluation of the influence of antiepileptic therapy on antioxidant enzyme activity and lipid peroxidation in erythrocytes of children with epilepsy. J Child Neurol 2006 Jul;21(7):558-62.

  14. Safar MM, Abdallah DM, Arafa NM, Abdel-Aziz MT. Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Res 2010 Jun 2;1334:58-64.

  15. Varoglu AO, Yildirim A, Aygul R, Gundogdu OL, Sahin YN. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clin Neuropharmacol 2010 May;33(3):155-7.

  16. Niketic V, Ristic S, Saicic ZS, Spasic M, Buzadzic B, Stojkovic M. Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with longterm antiepileptic therapy. Farmaco 1995 Nov;50(11):811-3.

  17. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010 Sep;8(3):254-67.

  18. Cengiz M, Yuksel A, Seven M. The effects of carbamazepine and valproic acid on the erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children. Pharmacol Res 2000 Apr;41(4):423-5.

  19. Ono H, Sakamoto A, Sakura N. Plasma total glutathione concentrations in epileptic patients taking anticonvulsants. Clin Chim Acta 2000 Aug;298(1-2):135-43.

  20. Liu CS, Wu HM, Kao SH, Wei YH. Serum trace elements, glutathione, copper/zinc superoxide dismutase, and lipid peroxidation in epileptic patients with phenytoin or carbamazepine monotherapy. Clin Neuropharmacol 1998 Jan;21(1):62-4.

  21. Mahle C, Dasgupta A. Decreased total antioxidant capacity and elevated lipid hydroperoxide concentrations in sera of epileptic patients receiving phenytoin. Life Sci 1997;61(4):437-43.

  22. Karabiber H, Yakinci C, Durmaz Y, Temel I, Mehmet N. Serum nitrite and nitrate levels in epileptic children using valproic acid or carbamazepine. Brain Dev 2004 Jan;26(1):15-8.

  23. Schulpis KH, Lazaropoulou C, Regoutas S, Karikas GA, Margeli A, Tsakiris S, et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006 Jan 16;217(2-3):228-32.

  24. Yis U, Seckin E, Kurul SH, Kuralay F, Dirik E. Effects of epilepsy and valproic acid on oxidant status in children with idiopathic epilepsy. Epilepsy Res 2009 Apr;84(2-3):232-7.

  25. Arhan E, Serdaroglu A, Ozturk B, Ozturk HS, Ozcelik A, Kurt N, et al. Effects of epilepsy and antiepileptic drugs on nitric oxide, lipid peroxidation and xanthine oxidase system in children with idiopathic epilepsy. Seizure 2011 Mar;20(2):138-42.

  26. Kurekci AE, Alpay F, Tanindi S, Gokcay E, Ozcan O, Akin R, et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia 1995 Jun;36(6):600-4.

  27. Yuksel A, Cengiz M, Seven M, Ulutin T. Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies. J Child Neurol 2001 Aug;16(8):603-6.

  28. Ozden H, Kabay SC, Toker A, Ustuner MC, Ozbayer C, Ustuner D, et al. The effects of levetiracetam on urinary 15f-2tisoprostane levels in epileptic patients. Seizure 2010 Oct;19(8):514-6.

  29. Bolayir E, Celik K, Tas A, Topaktas S, Bakir S. The effects of oxcarbazepine on oxidative stress in epileptic patients. Methods Find Exp Clin Pharmacol 2004 Jun;26(5):345-8.

  30. Martinc B, Grabnar I, Vovk T. Antioxidants as a preventive treatment for epileptic process: a review of the current status. Curr Neuropharmacol. 2014;12(6):527-50.

  31. Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, et al. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol Sci. 2012;130(1):4-16.

  32. Cardenas-Rodriguez N, Huerta-Gertrudis B, Rivera-Espinosa L, MontesinosCorrea H, Bandala C, Carmona-Aparicio L, et al. Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models. Int J Mol Sci. 2013;14(1):1455-76.

  33. Brieger K, Schiavone S, Miller FJ, Krause KH. Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012;142:w13659.

  34. D’Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8(10):813-24.

  35. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009;7(1):65-74.

  36. Mendez-Armenta M, Nava-Ruiz C, Juarez-Rebollar D, Rodriguez-Martinez E, Gomez PY. Oxidative stress associated with neuronal apoptosis in experimental models of epilepsy. Oxid Med Cell Longev. 2014;2014:293689.

  37. Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol. 2007;292(2):C641-57.

  38. Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res. 2000;40(1):33-9.

  39. Lopez J, Gonzalez ME, Lorigados L, Morales L, Riveron G, Bauza JY. Oxidative stress markers in surgically treated patients with refractory epilepsy. Clin Biochem. 2007;40(5-6):292-8.

  40. Ho YH, Lin YT, Wu CW, Chao YM, Chang AY, Chan JY. Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus. J Biomed Sci. 2015;22:46.

  41. Pecorelli A, Natrella F, Belmonte G, Miracco C, Cervellati F, Ciccoli L, et al. NADPH oxidase activation and 4-hydroxy-2-nonenal/aquaporin-4 adducts as possible new players in oxidative neuronal damage presents in drug-resistant epilepsy. Biochim Biophys Acta. 2015;1852(3):507-19.

  42. Chuang YC, Chen SD, Lin TK, Liou CW, Chang WN, Chan SH, et al. Upregulation of nitric oxide synthase II contributes to apoptotic cell death in the hippocampal CA3 subfield via a cytochrome c/caspase-3 signaling cascade following induction of experimental temporal lobe status epilepticus in the rat. Neuropharmacology. 2007;52(5):1263-73.

  43. Chuang YC, Chen SD, Liou CW, Lin TK, Chang WN, Chan SH, et al. Contribution of nitric oxide, superoxide anion, and peroxynitrite to activation of mitochondrial apoptotic signaling in hippocampal CA3 subfield following experimental temporal lobe status epilepticus. Epilepsia. 2009;50(4):731-46.

  44. Henshall DC. Apoptosis signalling pathways in seizure-induced neuronal death and epilepsy. Biochem Soc Trans. 2007;35(Pt 2):421-3.

  45. Vezzani A, Balosso S, Ravizza T. Inflammation and epilepsy. Handb Clin Neurol. 2012;107:163-75.

  46. Lorigados PL, Morales CL, Orozco SS, ocha AL. Pharmacoresistant epilepsy and immune system. In: Rocha AL, Cavalheiro EA, editors. Pharmacoresistance in Epilepsy. From Genes and Molecules to Promising Therapies. New York: Springer; 2013. p. 149-68.

  47. Ureña-Guerrero ME, Feria-Velasco A, Gudiño-Cabrera G, Camin-Espuny A, Beas-Zárate C. Modifications in the Seizures Susceptibility by Excitotoxic Neuronal Damage and Possible Relationship with the Pharmacoresistance. In: Rocha AL, Cavalheiro EA, editors. Pharmacoresistance in Epìlepsy. From Genes and Molecules to Promising Therapy.NY: Springer; 2013. p. 59-76.

  48. Lorigados L, Orozco S, Morales-Chacon L, Estupiñan B, García I, Rocha L. Excitotoxicity and neuronal death in epilepsy. Biotecnol Apl. 2013;30(1):9-16.

  49. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11-21.

  50. Riazi K, Galic MA, Pittman QJ. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res. 2010;89(1):34-42.

  51. Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci Lett. 2011;497(3):223-30.

  52. Eid T, Tu N, Lee TS, Lai JC. Regulation of astrocyte glutamine synthetase in epilepsy. Neurochem Int. 2013;63(7):670-81.

  53. Marchi N, Granata T, Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci. 2014;37(2):55-65.

  54. Touyz RM, Deng LY, He G, Wu XH, Schiffrin EL. Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens. 1999;17(7):907-16.

  55. De La Fuente M, Miquel J, Catalan MP, Victor VM, Guayerbas N. The amount of thiolic antioxidant ingestion needed to improve several immune functions is higher in aged than in adult mice. Free Radic Res. 2002;36(2):119-26.

  56. Viora M, Quaranta MG, Straface E, Vari R, Masella R, Malorni W. Redox imbalance and immune functions: opposite effects of oxidized low-density lipoproteins and N-acetylcysteine. Immunology. 2001;104(4):431-8.

  57. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J Biol Chem. 1999;274(4):2234-42.

  58. Dringen R, Gutterer JM, Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem. 2000;267(16):4912-6.

  59. Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci. 2010;2:12.

  60. Streit WJ. Microglia and the response to brain injury. Ernst Schering Res Found Workshop. 2002(39):11-24.

  61. Aronica E, Boer K, van Vliet EA, Redeker S, Baayen JC, Spliet WG, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis. 2007;26(3):497-511.

  62. Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis. 2008;29(1):142-60.

  63. Boer K, Crino PB, Gorter JA, Nellist M, Jansen FE, Spliet WG, et al. Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol. 2010;20(4):704-19.

  64. I yer A, Zurolo E, Spliet WG, van Rijen PC, Baayen JC, Gorter JA, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia. 2010;51(9):1763-73.

  65. Maldonado M, Baybis M, Newman D, Kolson DL, Chen W, McKhann G, 2nd, et al. Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis. 2003;14(2):279-90.

  66. Bauer S, Cepok S, Todorova-Rudolph A, Nowak M, Koller M, Lorenz R, et al. Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res. 2009;86(1):82-8.

  67. Eid T, Williamson A, Lee TS, Petroff OA, de Lanerolle NC. Glutamate and astrocytes- -key players in human mesial temporal lobe epilepsy? Epilepsia. 2008;49 Suppl 2:42-52.

  68. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium. 2003;34(4-5):325-37.

  69. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379-87.

  70. Sloviter RS. The neurobiology of temporal lobe epilepsy: too much information, not enough knowledge. C R Biol. 2005;328(2):143-53.

  71. Liang LP, Ho YS, Patel M. Mitochondrial superoxide production in kainateinduced hippocampal damage. Neuroscience. 2000;101(3):563-70.

  72. Shin EJ, Jeong JH, Chung YH, Kim WK, Ko KH, Bach JH, et al. Role of oxidative stress in epileptic seizures. Neurochem Int. 2011;59(2):122-37.

  73. Jarrett SG, Liang LP, Hellier JL, Staley KJ, Patel M. Mitochondrial DNA damage and impaired base excision repair during epileptogenesis. Neurobiol Dis. 2008;30(1): 130-8.

  74. Waldbaum S, Patel M. Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res. 2010;88(1):23-45.

  75. Waldbaum S, Liang LP, Patel M. Persistent impairment of mitochondrial and tissue redox status during lithium-pilocarpineinduced epileptogenesis. J Neurochem. 2010;115(5):1172-82.

  76. Dal-Pizzol F, Klamt F, Vianna MM, Schroder N, Quevedo J, Benfato MS, et al. Lipid peroxidation in hippocampus early and late after status epilepticus induced by pilocarpine or kainic acid in Wistar rats. Neurosci Lett. 2000;291(3):179-82.

  77. Cini M, Moretti A. Studies on lipid peroxidation and protein oxidation in the aging brain. Neurobiol Aging. 1995;16(1):53-7.

  78. Bruce AJ, Baudry M. Oxygen free radicals in rat limbic structures after kainate-induced seizures. Free Radic Biol Med. 1995;18(6):993- 1002.

  79. Frantseva MV, Perez Velazquez JL, Tsoraklidis G, Mendonca AJ, Adamchik Y, Mills LR, et al. Oxidative stress is involved in seizure-induced neurodegeneration in the kindling model of epilepsy. Neuroscience. 2000;97(3):431-5.

  80. Tejada S, Sureda A, Roca C, Gamundi A, Esteban S. Antioxidant response and oxidative damage in brain cortex after high dose of pilocarpine. Brain Res Bull. 2007;71(4):372-5.

  81. Folbergrova J, Kunz WS. Mitochondrial dysfunction in epilepsy. Mitochondrion. 2012;12(1):35-40.

  82. Bellissimo MI, Amado D, Abdalla DS, Ferreira EC, Cavalheiro EA, Naffah-Mazzacoratti MG. Superoxide dismutase, glutathione peroxidase activities and the hydroperoxide concentration are modified in the hippocampus of epileptic rats. Epilepsy Res. 2001;46(2):121-8.

  83. Patel M, Liang LP, Roberts LJ, 2nd. Enhanced hippocampal F2-isoprostane formation following kainate-induced seizures. J Neurochem. 2001;79(5):1065-9.

  84. Kudin AP, Kudina TA, Seyfried J, Vielhaber S, Beck H, Elger CE, et al. Seizure-dependent modulation of mitochondrial oxidative phosphorylation in rat hippocampus. Eur J Neurosci. 2002;15(7):1105-14.

  85. Waldbaum S, Patel M. Mitochondrial dysfunction and oxidative stress: a contributing link to acquired epilepsy? J Bioenerg Biomembr. 2010;42(6):449-55.

  86. Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chim Acta. 2001;303(1-2):19-24.

  87. Vielhaber S, Niessen HG, Debska-Vielhaber G, Kudin AP, Wellmer J, Kaufmann J, et al. Subfield-specific loss of hippocampal N-acetyl aspartate in temporal lobe epilepsy. Epilepsia. 2008;49(1):40-50.

  88. Heller A, Kunz M, Samakas A, Haase M, Kirschfink M, Koch T. The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock. 2000;13(4):285-90.

  89. Turkdogan D, Toplan S, Karakoc Y. Lipid peroxidation and antioxidative enzyme activities in childhood epilepsy. J Child Neurol. 2002;17(9):673-6.

  90. Aycicek A, Iscan A. The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children. Eur Neurol. 2007;57(2):65-9.

  91. Verrotti A, Basciani F, Trotta D, Pomilio MP, Morgese G, Chiarelli F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res. 2002;48(1-2):71-5.

  92. Gunes S, Dirik E, Yis U, Seckin E, Kuralay F, Kose S, et al. Oxidant status in children after febrile seizures. Pediatr Neurol. 2009;40(1):47-9.

  93. Lorigados Pedre L, Orozco Suarez S, Morales Chacon L, Garcia Maeso I, Estupinan Diaz B, Bender del Busto JE, et al. Neuronal death in the neocortex of drug resistant temporal lobe epilepsy patients. Neurologia. 2008;23(9):555-65.

  94. Lorigados Pedre L, Morales Chacon LM, Orozco Suarez S, Pavon Fuentes N, Estupinan Diaz B, Serrano Sanchez T, et al. Inflammatory mediators in epilepsy. Curr Pharm Des. 2013;19(38):6766-72.

  95. Estupinan-Diaz B, Morales-Chacon LM, Lorigados-Pedre L, Garcia-Maeso I, Benderdel Busto JE, Trapaga-Quincoses O, et al. Pathological neocortical findings in patients with medication-resistant medial temporal lobe epilepsy submitted to surgery. Rev Neurol. 2008;46(4):203-9.

  96. Vatassery GT. Vitamin E. Neurochemistry and implications for neurodegeneration in Parkinson’s disease. Ann N Y Acad Sci. 1992;669:97-109.

  97. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015;97:55-74.

  98. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012; 5(1):9-19.

  99. Naziroglu M, Yurekli VA. Effects of antiepileptic drugs on antioxidant and oxidant molecular pathways: focus on trace elements. Cell Mol Neurobiol. 2013;33(5):589-99.

  100. Freitas RM. The evaluation of effects of lipoic acid on the lipid peroxidation, nitrite formation and antioxidant enzymes in the hippocampus of rats after pilocarpine-induced seizures. Neurosci Lett. 2009;455(2):140-4.

  101. Cardenas-Rodriguez N, Coballase-Urrutia E, Huerta-Gertrudis B, Garcia-Cruz ME, Pedraza-Chaverri J, Coria-Jimenez R, et al. Antioxidant activity of topiramate: an antiepileptic agent. Neurol Sci. 2013;34(5):741-7.

  102. Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, et al. Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol. 2016;53(6):4094-125.

  103. Rong Y, Doctrow SR, Tocco G, Baudry M. EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc Natl Acad Sci U S A. 1999;96(17):9897-902.

  104. Gupta YK, Gupta M, Kohli K. Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian J Physiol Pharmacol. 2003;47(4):373-86.

  105. Kong Q, Lin CL. Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol Life Sci. 2010;67(11):1817- 29.

  106. Ambrogini P, Minelli A, Galati C, Betti M, Lattanzi D, Ciffolilli S, et al. Post-seizure alpha-tocopherol treatment decreases neuroinflammation and neuronal degeneration induced by status epilepticus in rat hippocampus. Mol Neurobiol. 2014;50(1):246-56.

  107. Holtzman D, Khait I, Mulkern R, Allred E, Rand T, Jensen F, et al. In vivo development of brain phosphocreatine in normal and creatine-treated rabbit pups. J Neurochem. 1999;73(6):2477-84.

  108. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 1998;30(2):153-8.

  109. Lima PA, Sampaio LP, Damasceno NR. Neurobiochemical mechanisms of a ketogenic diet in refractory epilepsy. Clinics (Sao Paulo). 2014;69(10):699-705.

  110. Auvin S. Fatty acid oxidation and epilepsy. Epilepsy Res. 2012;100(3):224-8.

  111. Giordano C, Marchio M, Timofeeva E, Biagini G. Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol. 2014;5:63.

  112. Jarrett SG, Milder JB, Liang LP, Patel M. The ketogenic diet increases mitochondrial glutathione levels. J Neurochem. 2008;106(3):1044-51.

  113. Milder J, Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res. 2012;100(3):295-303.

  114. Zamani GR, Mohammadi M, Ashrafi MR, Karimi P, Mahmoudi M, Badv RS, et al. The effects of classic ketogenic diet on serum lipid profile in children with refractory seizures. Acta Neurol Belg. 2016;116(4):529-34.




2020     |     www.medigraphic.com